Alnylam Pharmaceuticals (ALNY) Exchange Rate Effect (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Exchange Rate Effect came in at -$2.4 million in Q2 2026, down 108.89% YoY from $27.5 million in Q2 2025, and up 65.39% on a QoQ basis from -$7.1 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Exchange Rate Effect (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 9 years of Exchange Rate Effect data on file, last reported at -$2.4 million in Q2 2026.
- Quarterly Exchange Rate Effect fell 108.89% year-over-year to -$2.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$16.1 million (down 140.97% YoY) and the FY2025 annual result came in at $34.9 million, up 329.25% from the prior year.
- Exchange Rate Effect improved to -$2.4 million in Q2 2026, from -$7.1 million in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $27.5 million in Q2 2025 to a low of -$17.3 million in Q4 2024.
- A 5-year average of $508277.8 and a median of -$1.6 million in 2022 frame the typical range for Exchange Rate Effect.
- Annual changes were most pronounced in 2024 — Exchange Rate Effect tumbled 2300.0% — and 2025, when it soared 981.6%.
- Tracing ALNY's Exchange Rate Effect over 5 years: stood at $1.6 million in 2022, then surged by 573.07% to $10.9 million in 2023, then slumped by 258.49% to -$17.3 million in 2024, then jumped by 66.99% to -$5.7 million in 2025, then surged by 57.11% to -$2.4 million in 2026.
- The last three Exchange Rate Effect figures came in at -$2.4 million (Q2 2026), -$7.1 million (Q1 2026), and -$5.7 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 315,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.45 Mn |
| Jun 30, 2026 | -2.45 Mn |
| Mar 31, 2026 | -7.06 Mn |
| Mar 31, 2026 | -7.06 Mn |
| Dec 31, 2025 | -5.70 Mn |
| Dec 31, 2025 | -5.70 Mn |
| Sep 30, 2025 | -927,000.00 |
| Sep 30, 2025 | -927,000.00 |
| Jun 30, 2025 | 27.51 Mn |
| Jun 30, 2025 | 27.51 Mn |
| Mar 31, 2025 | 14.06 Mn |
| Mar 31, 2025 | 14.06 Mn |
| Dec 31, 2024 | -17.27 Mn |
| Dec 31, 2024 | -17.27 Mn |
| Sep 30, 2024 | 15.09 Mn |
| Sep 30, 2024 | 15.09 Mn |
| Jun 30, 2024 | -3.12 Mn |
| Jun 30, 2024 | -3.12 Mn |
| Mar 31, 2024 | -9.94 Mn |
| Mar 31, 2024 | -9.94 Mn |